How does your approach differ, if at all, in patients with Burkitt Leukemia in contrast to Burkitt Lymphoma?
We know that Burkitt Leukemia tends to do worse than isolated nodal Burkitt Lymphoma. Knowing this, would you approach high risk Burkitt leukemia (isolated >95% marrow involvement, LDH > 2500) similarly to ALL and consider upfront allogeneic SCT in a young and fit patient?